JP2009538348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538348A5 JP2009538348A5 JP2009512310A JP2009512310A JP2009538348A5 JP 2009538348 A5 JP2009538348 A5 JP 2009538348A5 JP 2009512310 A JP2009512310 A JP 2009512310A JP 2009512310 A JP2009512310 A JP 2009512310A JP 2009538348 A5 JP2009538348 A5 JP 2009538348A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- hydrogen
- alkyl
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 83
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 17
- 239000004475 Arginine Substances 0.000 claims description 16
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 16
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 16
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 229960003121 arginine Drugs 0.000 claims description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 16
- 235000009697 arginine Nutrition 0.000 claims description 16
- 229960002989 glutamic acid Drugs 0.000 claims description 16
- 235000013922 glutamic acid Nutrition 0.000 claims description 16
- 239000004220 glutamic acid Substances 0.000 claims description 16
- 229960003646 lysine Drugs 0.000 claims description 16
- 235000018977 lysine Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229960002429 proline Drugs 0.000 claims description 16
- 235000013930 proline Nutrition 0.000 claims description 16
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 15
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
- 229960005261 aspartic acid Drugs 0.000 claims description 14
- 235000003704 aspartic acid Nutrition 0.000 claims description 14
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 14
- 229960004441 tyrosine Drugs 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- 235000002374 tyrosine Nutrition 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 229960002449 glycine Drugs 0.000 claims description 13
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 11
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 11
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 11
- 239000004473 Threonine Substances 0.000 claims description 11
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 11
- 229960003767 alanine Drugs 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 229960001230 asparagine Drugs 0.000 claims description 11
- 235000009582 asparagine Nutrition 0.000 claims description 11
- 229960002433 cysteine Drugs 0.000 claims description 11
- 235000018417 cysteine Nutrition 0.000 claims description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 11
- 229960002743 glutamine Drugs 0.000 claims description 11
- 229960002885 histidine Drugs 0.000 claims description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 229960000310 isoleucine Drugs 0.000 claims description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 11
- 229960003136 leucine Drugs 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- 229960004452 methionine Drugs 0.000 claims description 11
- 229960005190 phenylalanine Drugs 0.000 claims description 11
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 11
- 229960001153 serine Drugs 0.000 claims description 11
- 229960002898 threonine Drugs 0.000 claims description 11
- 229960004799 tryptophan Drugs 0.000 claims description 11
- 229960004295 valine Drugs 0.000 claims description 11
- 239000004474 valine Substances 0.000 claims description 11
- 150000008575 L-amino acids Chemical group 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- -1 methylenedioxy Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- VKCQYGGIVBOTAJ-JTQLQIEISA-N (2s)-2-(1,3-benzodioxol-5-ylmethylamino)-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NCC1=CC=C2OCOC2=C1 VKCQYGGIVBOTAJ-JTQLQIEISA-N 0.000 claims description 5
- YRZDEQWWBMFRED-UHFFFAOYSA-N 2-amino-5-[benzoyl(carbamimidoyl)amino]pentanoic acid Chemical compound C(C1=CC=CC=C1)(=O)N(CCCC(N)C(=O)O)C(N)=N YRZDEQWWBMFRED-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 108010016626 Dipeptides Proteins 0.000 claims description 5
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 claims description 5
- SNEIUMQYRCDYCH-LURJTMIESA-N N(alpha)-acetyl-L-arginine Chemical compound CC(=O)N[C@H](C(O)=O)CCCNC(N)=N SNEIUMQYRCDYCH-LURJTMIESA-N 0.000 claims description 5
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical group O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 5
- 229960001410 hydromorphone Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 5
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical group O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- 229960005118 oxymorphone Drugs 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 230000000269 nucleophilic effect Effects 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 6
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 108090000765 processed proteins & peptides Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80908206P | 2006-05-26 | 2006-05-26 | |
| US60/809,082 | 2006-05-26 | ||
| US90179507P | 2007-02-16 | 2007-02-16 | |
| US60/901,795 | 2007-02-16 | ||
| PCT/US2007/069683 WO2007140272A2 (en) | 2006-05-26 | 2007-05-24 | Controlled release of phenolic opioids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013160111A Division JP2013224329A (ja) | 2006-05-26 | 2013-08-01 | フェノール性オピオイドの制御放出 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538348A JP2009538348A (ja) | 2009-11-05 |
| JP2009538348A5 true JP2009538348A5 (enExample) | 2010-07-08 |
| JP5371746B2 JP5371746B2 (ja) | 2013-12-18 |
Family
ID=38645732
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512310A Active JP5371746B2 (ja) | 2006-05-26 | 2007-05-24 | フェノール性オピオイドの制御放出 |
| JP2013160111A Withdrawn JP2013224329A (ja) | 2006-05-26 | 2013-08-01 | フェノール性オピオイドの制御放出 |
| JP2015022888A Withdrawn JP2015096554A (ja) | 2006-05-26 | 2015-02-09 | フェノール性オピオイドの制御放出 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013160111A Withdrawn JP2013224329A (ja) | 2006-05-26 | 2013-08-01 | フェノール性オピオイドの制御放出 |
| JP2015022888A Withdrawn JP2015096554A (ja) | 2006-05-26 | 2015-02-09 | フェノール性オピオイドの制御放出 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8217005B2 (enExample) |
| EP (2) | EP2046393B1 (enExample) |
| JP (3) | JP5371746B2 (enExample) |
| KR (1) | KR20090031519A (enExample) |
| AU (1) | AU2007267510B2 (enExample) |
| BR (1) | BRPI0712819B8 (enExample) |
| CA (1) | CA2653741C (enExample) |
| DK (1) | DK2046393T3 (enExample) |
| ES (1) | ES2456674T3 (enExample) |
| IL (1) | IL195360A (enExample) |
| MX (1) | MX2008014794A (enExample) |
| RU (1) | RU2469038C2 (enExample) |
| SG (1) | SG172633A1 (enExample) |
| WO (1) | WO2007140272A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172633A1 (en) * | 2006-05-26 | 2011-07-28 | Pharmacofore Inc | Controlled release of phenolic opioids |
| WO2008101202A1 (en) * | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | N-17-alkylated prodrugs of opioids |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US9023860B2 (en) | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
| WO2009092073A2 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| MX347741B (es) * | 2008-09-16 | 2017-05-10 | Nektar Therapeutics | Opioides pegilados con bajo potencial de abuso. |
| CA2739936C (en) | 2008-10-17 | 2017-12-12 | Pharmacofore, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
| WO2010100477A2 (en) * | 2009-03-03 | 2010-09-10 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| CA2756397A1 (en) * | 2009-04-02 | 2010-10-07 | Shire Llc | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof |
| US10849981B2 (en) | 2009-07-02 | 2020-12-01 | KemPham, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
| UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
| WO2011008636A1 (en) * | 2009-07-15 | 2011-01-20 | Mallinckrodt Inc. | 3-oxy-hydromorphone derivatives |
| JP2013503862A (ja) * | 2009-09-08 | 2013-02-04 | シグネーチャー セラピューティクス，インク． | 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 |
| WO2011041470A2 (en) * | 2009-09-30 | 2011-04-07 | Mallinckrodt Inc. | Sustained-release opiate and opiate derivative compositions |
| WO2011083304A1 (en) * | 2010-01-05 | 2011-07-14 | Shire Llc | Prodrugs of opioids and uses thereof |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| CA2795222A1 (en) * | 2010-04-21 | 2011-10-27 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| WO2011133151A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable phenol-modified opioid prodrugs and inhibitors thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US9238020B2 (en) * | 2010-04-21 | 2016-01-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug |
| US20110262359A1 (en) * | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| WO2012096886A1 (en) | 2011-01-11 | 2012-07-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| AU2012205733B2 (en) | 2011-01-11 | 2015-10-08 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| EP2683394B1 (en) | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| CN102920995B (zh) * | 2011-08-10 | 2015-08-26 | 辽宁药联制药有限公司 | 一种治疗肝损伤的药物组合物 |
| WO2013093931A2 (en) | 2011-09-19 | 2013-06-27 | Sun Pharma Advanced Research Company Ltd. | Novel prodrugs of phenolic drugs |
| JP5977355B2 (ja) | 2011-09-29 | 2016-08-24 | エコール ノルマル シュペリウール ドゥ リヨン | ペプチダーゼの蛍光発生基質 |
| IN2014DN03009A (enExample) | 2011-10-26 | 2015-05-08 | Kempharm Inc | |
| JP6270547B2 (ja) * | 2014-03-04 | 2018-01-31 | 公益財団法人微生物化学研究会 | 新規生物活性物質 |
| US10314839B2 (en) | 2014-10-20 | 2019-06-11 | Elysium Therapeutics, Inc. | Diversion-resistant opioid formulations |
| US11634384B2 (en) | 2014-11-25 | 2023-04-25 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| MX2017006520A (es) | 2014-11-25 | 2017-08-09 | Kempharm Inc * | Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico. |
| CA2969221C (en) | 2014-12-02 | 2021-01-12 | Travis Mickle | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof |
| WO2017059459A1 (en) * | 2015-10-01 | 2017-04-06 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| CA3025268A1 (en) | 2016-05-25 | 2017-11-30 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
| CA3056239C (en) | 2017-03-17 | 2023-09-12 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| CN111295368A (zh) * | 2017-09-22 | 2020-06-16 | 大日本住友制药株式会社 | 化学活化型水溶性前药 |
| US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
| US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
| US10717712B2 (en) | 2018-07-27 | 2020-07-21 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic TRPV1 agonists |
| US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
| CN117715632A (zh) | 2021-03-09 | 2024-03-15 | 恩赛斯生物科学股份有限公司 | 包含酶可裂解的前药和萘莫司他的组合物及其使用方法 |
| KR20230174213A (ko) | 2021-03-09 | 2023-12-27 | 엔사이스 바이오사이언시즈 인크. | 나파모스타트의 변형된 방출 조성물 및 그의 사용 방법 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| MX2024003466A (es) | 2021-09-29 | 2024-06-04 | Ensysce Biosciences Inc | Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos. |
| US11957676B1 (en) * | 2023-08-07 | 2024-04-16 | Zetagen Therapeutics, Inc. | Controlled release formulation and minimally invasive method of administration to locally treat cancer |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
| US3402240A (en) | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
| US3139383A (en) | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
| US3962414A (en) | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
| US3927036A (en) * | 1972-05-25 | 1975-12-16 | Abbott Lab | Basic carbonates and carbamates of benzopyrans |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3811444A (en) | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2336218C3 (de) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
| US4066747A (en) | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
| US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
| ZA791659B (en) | 1978-04-17 | 1980-04-30 | Ici Ltd | Process and apparatus for spraying liquid |
| US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| US4421736A (en) | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
| US4721613A (en) | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4820523A (en) | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
| US4752470A (en) | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
| US4816263A (en) | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
| US4853229A (en) | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
| GB9226717D0 (en) | 1992-12-22 | 1993-02-17 | Coffee Ronald A | Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories |
| GB9406171D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| GB9406255D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| GB9410658D0 (en) | 1994-05-27 | 1994-07-13 | Electrosols Ltd | Dispensing device |
| EP0814861B1 (en) | 1995-03-14 | 2002-06-05 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosing unit |
| IL117473A (en) | 1995-03-14 | 2001-08-26 | Siemens Ag | Ultrasonic atomizer device with removable precision dosating unit |
| US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| FR2779651B1 (fr) | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
| US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
| AU3699000A (en) * | 1999-03-10 | 2000-09-28 | Lotus Biochemical Corporation | Use of protein conformation for the protection and release of chemical compounds |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| JP2004523480A (ja) * | 2000-08-22 | 2004-08-05 | ニュー リバー ファーマシューティカルズ， インコーポレイテッド | 活性作用物質送達系ならびに活性作用物質の保護および投与方法 |
| US7056500B2 (en) | 2001-10-18 | 2006-06-06 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
| WO2003051113A1 (en) | 2001-12-14 | 2003-06-26 | The University Of Wyoming | Methods and compositions for controlled release of drugs |
| DE10161963A1 (de) * | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| AU2003219863C1 (en) | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| US20040086551A1 (en) | 2002-10-30 | 2004-05-06 | Miller Kenneth J. | Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl |
| EP1594513B1 (en) * | 2003-01-13 | 2011-08-10 | Shire LLC | Carbohydrate conjugates to prevent abuse of controlled substances |
| MXPA05009757A (es) | 2003-03-13 | 2005-12-05 | Controlled Chemicals Inc | Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida. |
| US8524272B2 (en) | 2003-08-15 | 2013-09-03 | Mylan Technologies, Inc. | Transdermal patch incorporating active agent migration barrier layer |
| EA008864B1 (ru) * | 2003-09-30 | 2007-08-31 | Нью Ривер Фармасьютикалз Инк. | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств |
| US7241807B2 (en) | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| WO2007005716A2 (en) * | 2005-06-30 | 2007-01-11 | Cinergen, Llc | Methods of treatment and compositions for use thereof |
| EP1928881A2 (en) * | 2005-08-19 | 2008-06-11 | Pharmacofore, Inc. | Prodrugs of active agents |
| SG172633A1 (en) * | 2006-05-26 | 2011-07-28 | Pharmacofore Inc | Controlled release of phenolic opioids |
| US20080207668A1 (en) | 2006-10-06 | 2008-08-28 | New River Pharmaceuticals Inc. | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse |
| US20090005444A1 (en) | 2007-06-21 | 2009-01-01 | Xenoport, Inc. | Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus |
| WO2009036322A1 (en) | 2007-09-14 | 2009-03-19 | Xenoport, Inc. | Use of propofol prodrugs for treating neuropathic pain |
-
2007
- 2007-05-24 SG SG2011037835A patent/SG172633A1/en unknown
- 2007-05-24 WO PCT/US2007/069683 patent/WO2007140272A2/en not_active Ceased
- 2007-05-24 JP JP2009512310A patent/JP5371746B2/ja active Active
- 2007-05-24 BR BRPI0712819A patent/BRPI0712819B8/pt active IP Right Grant
- 2007-05-24 AU AU2007267510A patent/AU2007267510B2/en active Active
- 2007-05-24 US US12/302,764 patent/US8217005B2/en active Active
- 2007-05-24 ES ES07797745.2T patent/ES2456674T3/es active Active
- 2007-05-24 KR KR1020087031374A patent/KR20090031519A/ko not_active Ceased
- 2007-05-24 EP EP07797745.2A patent/EP2046393B1/en active Active
- 2007-05-24 MX MX2008014794A patent/MX2008014794A/es active IP Right Grant
- 2007-05-24 CA CA2653741A patent/CA2653741C/en active Active
- 2007-05-24 RU RU2008151690/04A patent/RU2469038C2/ru active
- 2007-05-24 DK DK07797745.2T patent/DK2046393T3/da active
- 2007-05-24 EP EP11172570.1A patent/EP2402037B8/en active Active
-
2008
- 2008-11-18 IL IL195360A patent/IL195360A/en active IP Right Grant
-
2012
- 2012-06-01 US US13/486,613 patent/US8921418B2/en active Active
-
2013
- 2013-08-01 JP JP2013160111A patent/JP2013224329A/ja not_active Withdrawn
-
2014
- 2014-11-24 US US14/551,731 patent/US20150148284A1/en not_active Abandoned
-
2015
- 2015-02-09 JP JP2015022888A patent/JP2015096554A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10577337B2 (en) | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | |
| TWI440641B (zh) | 蛋白酶體抑制劑 | |
| JP2013503862A5 (enExample) | ||
| JP4151765B2 (ja) | 免疫調節活性を有する新規な置換プリニル誘導体 | |
| AU707144B2 (en) | Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect | |
| JP2013527124A (ja) | オピオイドの新規カルバマートアミノ酸およびペプチドプロドラッグならびにその使用 | |
| JP2007510621A5 (enExample) | ||
| RU2012108874A (ru) | Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы | |
| JP2013500304A5 (enExample) | ||
| JP2012509846A5 (enExample) | ||
| JP2013523599A (ja) | 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途 | |
| ES2968538T3 (es) | Compuestos útiles en la terapia del VIH | |
| CN109563133A (zh) | 多酰胺化合物及其用途 | |
| US20090186832A1 (en) | Amino acid peptide pro-drugs of phenolic analgesics and uses thereof | |
| KR20120089806A (ko) | 구안파신의 전구 약물 | |
| JP2011523645A5 (enExample) | ||
| JP2007505149A5 (enExample) | ||
| US20150202218A1 (en) | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections | |
| JP7830540B2 (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| CN101443332B (zh) | 抗病毒嘧啶核苷衍生物 | |
| ES2543199T3 (es) | Síntesis y usos de derivados del ácido piroglutámico | |
| US20090170937A1 (en) | Amino Acid Derivatives | |
| JP2005501121A5 (enExample) | ||
| JP2009510134A5 (enExample) | ||
| JP2002513764A5 (enExample) |